Eli Lilly's Cyramza (ramucirumab) Receives FDA's Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma
Shots:
- The approval is based on REACH‑2 study (NCT02435433) results assessing Cyramza (ramucirumab) + BSC vs PBO + BSC in 292 advanced HCC patients in the ratio (2:1) with alpha-fetoprotein (AFP) ≥ 400 ng/mL prior treated with sorafenib
- The REACH-2 study (NCT02435433) resulted in meeting its 1EPs i.e median OS (8.5mos. vs 7.3mos.)- mPFS (2.8 vs 1.6mos.)- ORR (4.6% vs 1.1%)
- Cyramza (ramucirumab- 8 mg/kg- q2w- IV) is a VEGFR2 antagonist and has received FDA’s approval as a monothx. or in combination with paclitaxel & docetaxel for advanced or m-gastric cancer & m-NSCLC respectively
- - Ref: US FDA- Eli Lilly | Image: Eli Lilly
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com